SIGILON THERAPEUTICS INC (SGTX) Stock Price & Overview
NASDAQ:SGTX • US82657L2060
The current stock price of SGTX is 22.47 USD. Today SGTX is down by -2.56%. In the past month the price increased by 4.95%. In the past year, price increased by 136.78%.
SGTX Key Statistics
- Market Cap
- 56.501M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -9.67
- Dividend Yield
- N/A
SGTX Stock Performance
SGTX Stock Chart
SGTX Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to SGTX. When comparing the yearly performance of all stocks, SGTX is one of the better performing stocks in the market, outperforming 99.58% of all stocks.
SGTX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to SGTX. Both the profitability and financial health of SGTX have multiple concerns.
SGTX Earnings
SGTX Forecast & Estimates
9 analysts have analysed SGTX and the average price target is 48.28 USD. This implies a price increase of 114.86% is expected in the next year compared to the current price of 22.47.
For the next year, analysts expect an EPS growth of -34.47% and a revenue growth 19.62% for SGTX
SGTX Groups
Sector & Classification
SGTX Financial Highlights
Over the last trailing twelve months SGTX reported a non-GAAP Earnings per Share(EPS) of -9.67. The EPS decreased by -327.88% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0.31 |
SGTX Ownership
SGTX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.25 | 401.392B | ||
| AMGN | AMGEN INC | 16.47 | 202.383B | ||
| GILD | GILEAD SCIENCES INC | 16.7 | 184.425B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.34 | 126.804B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.57 | 81.619B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 43.16 | 42.754B | ||
| INSM | INSMED INC | N/A | 31.007B | ||
| NTRA | NATERA INC | N/A | 28.197B | ||
| BIIB | BIOGEN INC | 11.66 | 27.651B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.75 | 23.485B | ||
| MRNA | MODERNA INC | N/A | 21.714B | ||
| EXAS | EXACT SCIENCES CORP | 340 | 19.732B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.591B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About SGTX
Company Profile
Sigilon Therapeutics, Inc. is a biopharmaceutical company, which engages in the research and development of therapeutic treatments for a wide range of chronic diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 62 full-time employees. The company went IPO on 2020-12-04. The firm is focused on developing functional cures for patients with acute and chronic diseases by providing stable and durable levels of therapeutic molecules to patients. The Company’s Shielded Living Therapeutics (SLTx) platform is comprised of two primary elements: the cells and the sphere. The Company’s lead product candidate, SIG-002, is designed to replace islet cells for the treatment of Type 1 Diabetes (T1D). The company is also developing product candidates for the treatment of lysosomal diseases. Its program for diabetes, it focused to apply the SLTx platform to develop product candidates, including product candidates for patients with liver and immune mediated diseases, and explore delivery of different molecules and alternative routes of administration. The company also engineers cells to express a therapeutic molecule of choice in a continuous manner, which it refers to as constitutive expression.
Company Info
IPO: 2020-12-04
SIGILON THERAPEUTICS INC
100 Binney Street, Ste 600
Cambridge MASSACHUSETTS US
Employees: 62
Phone: 16173367540.0
SIGILON THERAPEUTICS INC / SGTX FAQ
What does SGTX do?
Sigilon Therapeutics, Inc. is a biopharmaceutical company, which engages in the research and development of therapeutic treatments for a wide range of chronic diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 62 full-time employees. The company went IPO on 2020-12-04. The firm is focused on developing functional cures for patients with acute and chronic diseases by providing stable and durable levels of therapeutic molecules to patients. The Company’s Shielded Living Therapeutics (SLTx) platform is comprised of two primary elements: the cells and the sphere. The Company’s lead product candidate, SIG-002, is designed to replace islet cells for the treatment of Type 1 Diabetes (T1D). The company is also developing product candidates for the treatment of lysosomal diseases. Its program for diabetes, it focused to apply the SLTx platform to develop product candidates, including product candidates for patients with liver and immune mediated diseases, and explore delivery of different molecules and alternative routes of administration. The company also engineers cells to express a therapeutic molecule of choice in a continuous manner, which it refers to as constitutive expression.
What is the current price of SGTX stock?
The current stock price of SGTX is 22.47 USD. The price decreased by -2.56% in the last trading session.
What is the dividend status of SIGILON THERAPEUTICS INC?
SGTX does not pay a dividend.
What is the ChartMill technical and fundamental rating of SGTX stock?
SGTX has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What do analysts say about SIGILON THERAPEUTICS INC (SGTX) stock?
9 analysts have analysed SGTX and the average price target is 48.28 USD. This implies a price increase of 114.86% is expected in the next year compared to the current price of 22.47.
When does SIGILON THERAPEUTICS INC (SGTX) report earnings?
SIGILON THERAPEUTICS INC (SGTX) will report earnings on 2023-11-08, after the market close.